Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma

Reuters

Nov 10

Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma

Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma $(BCC)$. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582984141"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582984141\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582984141?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582984141","market":"fut","top_or_hot":-1,"title":"Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRCA","symbol_name":"Verrica Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbR0290:1","article_id":"2582984141","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582984141","pubTimestamp":1762754446,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma . Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8 and helper CD4 T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Troms on November 11, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRCA":"Verrica Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Lytix Biopharma报告Ruxotemitide治疗基底细胞癌的强劲II期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    \n\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma $(BCC)$. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}